Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET
Company Participants
Pia Eaves – Vice President-Investor Relations and Strategy
Terry Rosen – Chief Executive Officer
Jennifer Jarrett – Chief Operating Officer
Bob Goeltz – Chief Financial Officer
Dimitry Nuyten – Chief Medical Officer
Conference Call Participants
Yigal Nochomovitz – Citi
Jonathan Miller – Evercore
Daina Graybosch – Leerink Partners
Asthika Goonewardene – Truist Securities
Operator
Good afternoon, thank you for attending today's Arcus Biosciences Second Quarter 2024 Earnings Call. My name is Tamiya and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. [Operator Instructions]
I would now like to pass the conference over to your host, Pia Eaves, Vice President of Investor Relations and Strategy. You may proceed.
Pia Eaves
Hello, everyone, and thank you for joining us on today's conference call to discuss Arcus' second quarter 2024 financial results and pipeline updates. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway and our expected clinical development milestones and timelines.
All statements, other than historical facts, reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q, that has been filed with the SEC. We strongly encourage you to review our filings.
Today, you'll hear from our CEO, Terry Rosen; COO, Jennifer Jarrett; and CFO, Bob Goeltz. We'll also be joined by our; CMO, Dimitry Nuyten; and President, Juan Jaen for questions after the prepared remarks.
With that, I'll turn the call over to Terry.
Terry Rosen
Thanks very much, Pia, and thank you all for joining us this afternoon. 2024 has already been a very exciting year for us and also very consequential. We completed enrollment of our first Phase 3 trial, STAR-221, a 1,000-plus patient study in first-line upper GI adenocarcinomas. And we're on the brink of advancing two additional molecules into Phase 3 studies, both of which are supported by strong data and targeting huge unmet needs and market opportunities.
Casdatifan, or cas, our HIF-2 alpha inhibitor, will be our newest Phase 3 entrant. We're going to share a lot of information about this program today and, in fact, throughout the rest of the year. The HIF-2-alpha inhibition mechanism has been clinically validated by the approval of Merck's belzutifan, which has been shown to have robust single-agent activity in clear cell renal cell carcinoma, or clear cell RCC, as we'll call it throughout the call.